98%
921
2 minutes
20
Patients with atopic dermatitis (AD) often experience symptoms of skin dryness, coinfection, oxidative damage, immune dysfunction, and inflammatory response. Clinical recommendations typically include antibiotics, glucocorticoids, and immunosuppressants, but frequent use of these medications can lead to drug resistance and adverse side effects. Herein, a pH/ROS-responsive injectable dual network hydrogel (HCFP) was developed by cross-linking oxidized hyaluronic acid, quaternized chitosan, and proanthocyanidins (PA) for the treatment of atopic dermatitis (AD). The HCFP hydrogel exhibited robust adhesive and self-healing properties, preventing delamination by scratching while enhancing the penetration of PA into the stratum corneum. In vitro and in vivo studies showed that HCFP effectively restored the skin barrier, suppressed bacterial infection, alleviated oxidative stress, modulated the immune response, and reduced inflammation, outperforming clinical dexamethasone ointment. This multifunctional hydrogel, which combines antibacterial, antioxidant, immunomodulatory, and anti-inflammatory properties, represents a promising therapeutic dressing for the treatment of AD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.biomac.5c00486 | DOI Listing |
J Invest Dermatol
September 2025
Department of Dermatology, Keck School of Medicine of University of South California, Los Angeles, California, USA; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. Electronic address:
This review examines the roles of galectins, a family of animal lectins, in inflammatory skin diseases, focusing on their involvement in the pathogenesis of psoriasis, atopic dermatitis, contact dermatitis, and common autoimmune diseases. We highlight the differential expression of galectins in lesional skin and their correlation with inflammatory mediators. In addition, we summarize the functions and mechanisms of action of endogenous galectins, as revealed through studies of genetically engineered cell lines and experimental animals.
View Article and Find Full Text PDFJ Invest Dermatol
September 2025
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Sibel Health, Chicago, Illinois, USA; Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois, USA. Electronic address:
The integration of wearable medical devices and digital health technologies (DHTs) in health care has grown significantly during the past 2 decades, particularly in dermatology, in which objective measurement of symptoms such as itch remains challenging. This review examines the evolution of DHTs in dermatology, focusing on the validation frameworks necessary for their implementation in clinical trials and research. We discuss the key stages of validation: hardware validation to ensure device reliability, analytical validation to transform raw sensor data into meaningful metrics, and clinical validation to demonstrate utility in specific patient populations.
View Article and Find Full Text PDFClin Exp Dermatol
September 2025
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Sleep
September 2025
Instituto do Sono, Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil.
J Vet Pharmacol Ther
September 2025
Elanco Animal Health, Sèvres, France.
Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.
View Article and Find Full Text PDF